MeiraGTx Holdings plc

NASDAQ:MGTX

Biotechnology

Healthcare
$8.32 +5.08%

+$0.53 today

Market cap
$813.12M
Beta
1.26
P/E (TTM)
-7.4
EPS (TTM)
-$1.48
52W Low $6.07High $11.85

Volume 0.58M

Average 0.84M

MGTX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

MeiraGTx Holdings plcNASDAQ: MGTX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 81.3M shares rose 2.9% year over year, behind the +13.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at +21.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.9% toward the trailing-twelve-month pace of +13.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
81.3M+0.2% QoQ
Last fiscal yearDec 2025
80.43M+15.2% YoY
LTMMar 2026
80.99M+13.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.9%——
1 year+15.2%——
3-year CAGR+21.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
80.43M USD
Year-over-year change
+15.2%
4-year CAGR
+16.2%

Weighted Avg Shares vs competitors

How MGTX compares with its peers on the latest reported figures

  • MGTX's LTM Mar 2026 weighted avg shares of 80.99M shares is the 5th highest of the 9 companies compared; the peer median is 84.85M shares.
  • Its year-over-year change of +13.7% is the 3rd highest of 9, against a peer median of +9.2%.
  • Over three fiscal years its annual growth of +21.2% compares with a peer median of +10.5%.
MGTX Competitors Peer median
Weighted Avg Shares for MGTX and competitors
Company Period LTM YoY 3-year CAGR
OCGNOcugen, Inc.LTM Mar 2026307.2M +9.9%+11.8%
SANASana Biotechnology, Inc.LTM Mar 2026257.25M +9.0%+10.4%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026233.09M +16.0%+10.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
MGTXMeiraGTx Holdings plcLTM Mar 202680.99M +13.7%+21.2%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
QUREuniQure N.V.LTM Mar 202658.39M +17.2%+7.2%
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
KRYSKrystal Biotech, Inc.LTM Jun 202629.18M +1.3%+4.3%
Peer median (excluding MGTX) 84.85M+9.2%+10.5%

Competitors are the stored peer set for MGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.7M15.92M14.02M33.28M81.39M
Cost of Revenue00023.79M4.84M
Gross Profit37.7M15.92M14.02M9.49M76.55M
Gross Margin100.0%100.0%100.0%28.5%94.0%
Research & Development66.69M85.73M103.79M119.48M129.62M
Selling, General & Admin43.77M46.55M47.29M54.22M52.9M
Operating Expenses110.46M132.28M151.08M173.7M182.52M
Depreciation & Amortization7.87M8.6M13.73M12.83M12.61M
EBITDA(71.4M)(116.07M)(57.05M)(121.69M)(89.4M)
EBITDA Margin-189.4%-729.1%-407.0%-365.7%-109.8%
Operating Income(72.76M)(116.36M)(137.06M)(164.21M)(105.97M)
Operating Margin-193.0%-730.9%-977.8%-493.4%-130.2%
Interest Income212K777K2.27M4.15M1.82M
Interest Expense288K4.95M13.25M13.27M12.2M
Other Income / Expenses(6.8M)(13.26M)53.03M16.42M(8.23M)
Income Before Tax(79.56M)(129.62M)(84.03M)(147.79M)(114.2M)
Pre-Tax Margin-211.0%-814.2%-599.5%-444.1%-140.3%
Income Tax Expense00000
Net Income(79.56M)(129.62M)(84.03M)(147.79M)(114.2M)
Net Margin-211.0%-814.2%-599.5%-444.1%-140.3%
EPS (Basic)(1.80)(2.87)(1.49)(2.12)(1.42)
EPS (Diluted)(1.80)(2.87)(1.49)(2.12)(1.42)
Weighted Avg Shares44.14M45.18M56.49M69.82M80.43M
Weighted Avg Shares (Diluted)44.14M45.18M56.49M69.82M80.43M

MeiraGTx Holdings plc

NASDAQ:MGTX

Intrinsic Alpha fair value

Locked

Current Price

$8.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.